Prescribing information



TAFINLAR + MEKINIST: a well-established safety profile 


TAFINLAR in combination with MEKINIST is indicated in adult patients for the treatment of BRAF V600 positive, unresectable or metastatic melanoma, and in the adjuvant setting for Stage III BRAF V600 positive melanoma, following complete resection.1,2

TAFINLAR and MEKINIST are also licensed as monotherapies for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.1,2

Please refer to the respective SmPCs for all licensed indications.

This page relates to the safety profile of the combination therapy in melanoma only. Please refer to the individual summary of product characteristics to view the safety data for each monotherapy and in BRAF V600+ NSCLC.1,2

The adverse events and special warning/precautions discussed here may also occur with trametinib and dabrafenib monotherapy.


For information on managing select adverse events and related dosing, please see the dosing modification page


Adverse reactions reported in the integrated safety population of TAFINLAR + MEKINIST in the studies MEK115306, MEK116513,* BRF113928, and BRF115532 (n=1076)1,2

The corresponding frequency for each adverse drug reaction is based on the following: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).1,2

Adverse reactions table of Tafinlar and Mekinist in clinical studies.

Table adapted from TAFINLAR + MEKINIST Summaries of Product Characteristics.1,2 


TAFINLAR contraindications: Hypersensitivity to the active substance or to the following excipients: microcrystalline cellulose, magnesium stearate, colloidal silicone dioxide, red iron oxide (E172), titanium dioxide (E171), hypromellose (E464), block iron oxide (E172), shellac, propylene glycol.1

MEKINIST contraindications: Hypersensitivity to the active substance or to the following excipients: mannitol (E421), microcrystalline cellulose (E460), hypromellose (E464), croscarmellose sodium (E468), magnesium stearate (E470b), sodium laurilsulfate, colloidal silicon dioxide (E551), titanium dioxide (E171), polyethylene glycol, iron oxide yellow (E172), polysorbate 80 (E433) and iron oxide red (E172).2

Special warnings and precautions for use1,2

When TAFINLAR is given in combination with MEKINIST, the SmPC of TAFINLAR and MEKINIST must be consulted prior to initiation of combination treatment. For additional information on warnings and precautions associated with treatment, please refer to the respective SmPC.

BRAF V6000 testing
The efficacy and safety of TAFINLAR + MEKINIST has not been evaluated in patients whose melanoma tested negative for the BRAF V600 mutation. TAFINLAR should not be used in patients with wild-type BRAF melanoma and NSCLC.

Dabrafenib in combination with trametinib in patients with melanoma who have progressed on a BRAF inhibitor
There are limited data in patients taking the combination of TAFINLAR + MEKINIST who have progressed on a prior BRAF inhibitor. These data show that the efficacy of the combination will be lower in these patients. Therefore, other treatment options should be considered before treatment with the combination in this prior BRAF inhibitor treated population. The sequencing of treatments following progression on a BRAF inhibitor therapy has not been established.

New malignancies
New malignancies, cutaneous and non-cutaneous, can occur with TAFINLAR + MEKINIST. 

Cutaneous malignancies
Cutaneous squamous cell carcinoma (cuSCC)
Cases of cuSCC (including keratoacanthoma) have been reported in patients treated with TAFINLAR + MEKINIST. In the integrated safety population of patients with melanoma and advanced NSCLC, cuSCC occurred in 2% (19/1076) of patients receiving TAFINLAR + MEKINIST. The median time to diagnosis of the first occurrence of cuSCC in study MEK115306 was 223 days (range 56 to 510 days) in the combination therapy arm and 60 days (range 9 to 653 days) in the TAFINLAR monotherapy arm. In the Phase III study BRF115532 (COMBI-AD) in the adjuvant treatment of melanoma, 1% (6/435) of patients receiving TAFINLAR + MEKINIST as compared to 1% (5/432) of patients receiving placebo developed cuSCC. The median time to onset of the first occurrence of cuSCC in the combination arm of the adjuvant treatment study was approximately 18 weeks and was 33 weeks in the placebo arm.

It is recommended that skin examination be performed prior to initiation of therapy with dabrafenib and monthly throughout treatment and for up to six months after treatment for cuSCC. Monitoring should continue for 6 months following discontinuation or until initiation of another anti-neoplastic therapy.

Cases of cuSCC should be managed by dermatological excision, if taken in combination, TAFINLAR + MEKINIST should be continued without any dose adjustment. Patients should be instructed to immediately inform their physician if new lesions develop.

New primary melanoma
New primary melanoma was reported in patients receiving TAFINLAR + MEKINIST. Cases of new primary melanoma can be managed with excision and do not require treatment modification. Monitoring for skin lesions should occur as described for cuSCC.

Non-cutaneous malignancies
In vitro experiments have demonstrated paradoxical activation of mitogen-activated protein kinase (MAP kinase) signalling in BRAF wild-type cells with RAS mutations when exposed to BRAF inhibitors. This may lead to increased risk of non-cutaneous malignancies with dabrafenib exposure when RAS mutations are present. RAS-associated malignancies have been reported in clinical trials with TAFINLAR + MEKINIST (colorectal cancer, pancreatic cancer).

Prior to initiation of treatment, patients should undergo a head and neck examination with minimally visual inspection of oral mucosa and lymph node palpation, as well as chest/abdomen computerised tomography (CT) scan. During treatment, patients should be monitored as clinically appropriate which may include a head and neck examination every 3 months and a chest/abdomen CT scan every 6 months. Anal examinations and pelvic examinations are recommended before and at the end of treatment or when considered clinically indicated. Complete blood cell counts and blood chemistry should be performed as clinically indicated.

The benefits and risks should be considered before administering in patients with a prior or concurrent cancer associated with RAS mutations. No dose modification of trametinib is required with TAFINLAR + MEKINIST.

Following discontinuation, monitoring for non-cutaneous secondary/recurrent malignancies should continue for up to 6 months or until initiation of another anti-neoplastic therapy. Abnormal findings should be managed according to clinical practices.

Haemorrhagic events, including major haemorrhagic and fatal haemorrhages, have occurred in patients taking TAFINLAR + MEKINIST. The potential for these events in patients with low platelet counts (<75,000) has not been established, as such patients were excluded from clinical trials. The risk of haemorrhage may be increased with concomitant use of antiplatelet or anticoagulant therapy. If haemorrhage occurs, patients should be treated as clinically indicated.

Visual impairment
In clinical trials ophthalmologic reactions, including uveitis, iridocyclitis and iritis, have been reported in patients treated with TAFINLAR + MEKINIST. Patients should be routinely monitored for visual signs and symptoms (such as change in vision, photophobia and eye pain) while on therapy.

No dose modifications are required as long as effective local therapies can control ocular inflammation. If uveitis does not respond to local ocular therapy, withhold dabrafenib until resolution of ocular inflammation and then restart dabrafenib reduced by one dose level. No dose modification of TAFINLAR is required when taken in combination with MEKINIST following diagnosis of uveitis.

RPED and RVO may occur with TAFINLAR + MEKINIST. No dose modification of TAFINLAR is required when taken in combination with MEKINIST following diagnosis of RVO or RPED.

Fever has been reported in clinical trials with TAFINLAR + MEKINIST. 

The incidence and severity of pyrexia are increased with combination therapy. In the combination therapy arm of study MEK115306 in patients with unresectable or metastatic melanoma, pyrexia was reported in 57% (119/209) of patients with 7% Grade 3, as compared to the TAFINLAR monotherapy arm with 33% (69/211) of patients reporting pyrexia, 2% Grade 3. In the Phase II study BRF113928 in patients with advanced NSCLC the incidence and severity of pyrexia were increased slightly when TAFINLAR was used in combination with MEKINIST (48%, 3% Grade 3) as compared to dabrafenib monotherapy (39%, 2% Grade 3). In the Phase III study BRF115532 in the adjuvant treatment of melanoma, the incidence and severity of pyrexia were higher in the TAFINLAR + MEKINIST arm (67%; 6% Grade 3/4) as compared to the placebo arm (15%; <1% Grade 3).

For patients with unresectable or metastatic melanoma who received TAFINLAR + MEKINIST and developed pyrexia, approximately half of the first occurrences of pyrexia happened within the first month of therapy and approximately one-third of the patients had 3 or more events.

Therapy should be interrupted if the patient's temperature is ≥38°C. In case of recurrence, therapy can also be interrupted at the first symptom of pyrexia. Treatment with anti-pyretics such as ibuprofen or acetaminophen/paracetamol should be initiated. The use of oral corticosteroids should be considered in those instances in which anti-pyretics are insufficient. Patients should be evaluated for signs and symptoms of infection. Therapy can be restarted once the fever resolves. If fever is associated with other severe signs or symptoms, therapy should be restarted at a reduced dose once fever resolves and as clinically appropriate.

LVEF reduction/Left ventricular dysfunction
TAFINLAR + MEKINIST has been reported to decrease LVEF. No dose modification is required. In patients receiving TAFINLAR in combination with MEKINIST, there have been occasional reports of acute, severe left ventricular dysfunction due to myocarditis. Full recovery was observed when stopping treatment. Physicians should be alert to the possibility of myocarditis in patients who develop new or worsening cardiac signs or symptoms. Trametinib should be used with caution in patients with impaired left ventricular function. LVEF should be evaluated in all patients prior to initiation of treatment with trametinib, one month after initiation of therapy, and then at approximately 3-monthly intervals while on treatment.

Renal failure
Renal failure has been identified in ≤1% of patients treated with TAFINLAR + MEKINIST. Observed cases were generally associated with pyrexia and dehydration and responded well to dose interruption and general supportive measures. Granulomatous nephritis has been reported. Patients should be routinely monitored for serum creatinine while on therapy. If creatinine increases, TAFINLAR may need to be interrupted as clinically appropriate. TAFINLAR has not been studied in patients with renal insufficiency (defined as creatinine >1.5 x ULN), therefore caution should be used in this setting.

Hepatic events
Hepatic adverse events have been reported in clinical trials with TAFINLAR + MEKINIST. It is recommended that patients receiving treatment with TAFINLAR + MEKINIST have liver function monitored every four weeks for 6 months after treatment initiation with trametinib. Liver monitoring may be continued thereafter as clinically indicated. 

Elevations in blood pressure have been reported in association with TAFINLAR + MEKINIST, in patients with or without pre-existing hypertension. Blood pressure should be measured at baseline and monitored during treatment with MEKINIST, with control of hypertension by standard therapy as appropriate.

Interstitial lung disease (ILD)/Pneumonitis
Cases of pneumonitis or ILD have been reported in clinical trials with TAFINLAR + MEKINIST. MEKINIST should be withheld in patients with suspected ILD or pneumonitis, including patients presenting with new or progressive pulmonary symptoms and findings including cough, dyspnoea, hypoxia, pleural effusion, or infiltrates, pending clinical investigations. MEKINIST should be permanently discontinued for patients diagnosed with treatment-related ILD or pneumonitis. If TAFINLAR is being used in combination with MEKINIST then therapy with TAFINLAR may be continued at the same dose.

Rash has been observed in about 24% of patients in clinical trials with TAFINLAR + MEKINIST. The majority of these cases were Grade 1 or 2 and did not require any dose interruptions or dose reductions.

Rhabdomyolysis has been reported in patients taking TAFINLAR + MEKINIST. In some cases, patients were able to continue MEKINIST. In more severe cases hospitalisation, interruption or permanent discontinuation of MEKINIST or TAFINLAR + MEKINIST was required. Signs or symptoms of rhabdomyolysis should warrant an appropriate clinical evaluation and treatment as indicated.

Pancreatitis has been reported in <1% of patients treated with TAFINLAR + MEKINIST in unresectable or metastatic melanoma clinical trials and about 4% of patients treated with TAFINLAR + MEKINIST in the NSCLC clinical trial. In the adjuvant treatment of melanoma trial, pancreatitis was reported in <1% (1/435) of patients receiving TAFINLAR + MEKINIST, and no patients receiving placebo. Unexplained abdominal pain should be promptly investigated to include measurement of serum amylase and lipase. Patients should be closely monitored when re-starting TAFINLAR after an episode of pancreatitis.

Deep vein thrombosis/Pulmonary embolism
Pulmonary embolism or deep vein thrombosis can occur with TAFINLAR + MEKINIST. If patients develop symptoms of pulmonary embolism or deep vein thrombosis such as shortness of breath, chest pain, or arm or leg swelling, they should immediately seek medical care. Permanently discontinue TAFINLAR + MEKINIST for life-threatening pulmonary embolism.

Severe cutaneous adverse reactions
Cases of severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome, and drug reaction with eosinophilia and systemic symptoms (DRESS), which can be life-threatening or fatal, have been reported during treatment with TAFINLAR + MEKINIST. Before initiating treatment, patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of SCARs appear, TAFINLAR + MEKINIST should be withdrawn.

Gastrointestinal disorders
Colitis and gastrointestinal perforation, including fatal outcome, have been reported in patients taking TAFINLAR + MEKINIST. Treatment with MEKINIST monotherapy or TAFINLAR + MEKINIST should be used with caution in patients with risk factors for gastrointestinal perforation, including history of diverticulitis, metastases to the gastrointestinal tract and concomitant use of medicinal products with a recognised risk of gastrointestinal perforation.

Cases of sarcoidosis have been reported in patients treated TAFINLAR + MEKINIST, mostly involving the skin, lung, eye and lymph nodes. In the majority of the cases, treatment with TAFINLAR + MEKINIST was maintained. In case of a diagnosis of sarcoidosis, relevant treatment should be considered. It is important not to misinterpret sarcoidosis as disease progression.

Haemophagocytic lymphohistiocytosis
In post-marketing experience, haemophagocytic lymphohistiocytosis (HLH) has been observed in patients treated with TAFINLAR + MEKINIST. Caution should be taken when MEKINIST is administered in combination with TAFINLAR. If HLH is confirmed, administration of TAFINLAR + MEKINIST should be discontinued and treatment for HLH initiated.

MEKINIST contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially “sodium-free”.

Effects of other medicinal products on dabrafenib
TAFINLAR is a substrate of CYP2C8 and CYP3A4. Potent inducers of these enzymes should be avoided when possible, as these agents may decrease the efficacy of TAFINLAR.

Effects of dabrafenib on other medicinal products
TAFINLAR is an inducer of metabolising enzymes which may lead to loss of efficacy of many commonly used medicinal products. A drug utilisation review (DUR) is therefore essential when initiating TAFINLAR treatment. Concomitant use of TAFINLAR with medicinal products that are sensitive substrates of certain metabolising enzymes or transporters should generally be avoided if monitoring for efficacy and dose adjustment is not possible.

Concomitant administration of TAFINLAR with warfarin results in decreased warfarin exposure. Caution should be exercised and additional International Normalised Ratio (INR) monitoring is recommended when TAFINLAR is used concomitantly with warfarin and at discontinuation of TAFINLAR.

Concomitant administration of TAFINLAR with digoxin may result in decreased digoxin exposure. Caution should be exercised and additional monitoring of digoxin is recommended when digoxin (a transporter substrate) is used concomitantly with TAFINLAR and at discontinuation of TAFINLAR.

Please refer to the individual summary of product characteristics for all potential interactions and associated guidance.1,2

In a pooled five-year analysis of patients with metastatic melanoma, the most common adverse events observed with TAFINLAR + MEKINIST included pyrexia, nausea, diarrhoea, fatigue, headache, chills, and vomiting.3


In a study of patients with Phase III melanoma, the most common adverse events observed with TAFINLAR + MEKINIST as an adjunct therapy included pyrexia, fatigue and nausea.4


Please use the buttons below to find out more regarding the safety profile of TAFINLAR + MEKINIST in BRAF V600 positive metastatic or unresectable melanoma or as an adjunct therapy in Phase III melanoma following complete resection.

For information on dose reduction, treatment interruption and treatment discontinuation please click the link below

Please note this is not an exhaustive summary of the safety profile. Please consult the TAFINLAR + MEKINIST Summary of Product Characteristics for a full list of adverse events.





Please visit the management of patients with BRAF V600-positive melanoma page for further information on monitoring for, and managing, pyrexia and other adverse events in patients receiving TAFINLAR + MEKINIST.1,2

*The safety profile from MEK116513 is generally similar to that of MEK115306 with the following exceptions: 1) The following adverse reactions have a higher frequency category as compared to MEK115306: muscle spasm (very common); renal failure and lymphoedema (common); acute renal failure (uncommon); 2) The following adverse reactions have occurred in MEK116513 but not in MEK115306: cardiac failure, left ventricular dysfunction, interstitial lung disease (uncommon). 3) The following adverse reaction has occurred in MEK116513 and BRF115532 but not in MEK115306 and BRF113928: rhabdomyolysis (uncommon).1,2
Cutaneous squamous cell carcinoma (cuSCC): SCC, SCC of the skin, SCC in situ (Bowen's disease) and keratoacanthoma.
Papilloma, skin papilloma.
§Malignant melanoma, metastatic malignant melanoma, and superficial spreading melanoma Stage III.
Includes drug hypersensitivity.
IIBleeding from various sites, including intracranial bleeding and fatal bleeding
**Abdominal pain upper and abdominal pain lower.
††Erythema, generalised erythema.
‡‡Muscle spasms, musculoskeletal stiffness.

CT, computerised tomography; cuSCC, cutaneous squamous cell carcinoma; DRESS, drug reaction with eosinophilia and systemic symptoms; ILD, interstitial lung disease; LVEF, left ventricular ejection fraction; MAP, mitogen-activated protein; NSCLC, non small cell lung cancer; RPED, retinal pigment epithelial dystrophy; RVO, retinal vein occlusion; SCAR, severe cutaneous adverse reaction; SCC, squamous cell carcinoma.


  1. Tafinlar (dabrafenib) Summary of Product Characteristics.
  2. Mekinist (trametinib) Summary of Product Characteristics.
  3. Robert C, et al. N Engl J Med 2019;381:626–636.
  4. Long GV, et al. N Engl J Med 2017;377:1813–1823.
Rate this content: 
Average: 4 (1 vote)
UK | September 2023 | 294258

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]